Vivek Subbiah: Setting Off on the Mission to Target KRAS in Colorectal Cancer
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn about recent paper he and his colleagues authored:
“With so many KRAS targeted drugs entering clinical trials pleased to share our editorial in American Society of Clinical Oncology (ASCO) journal JCO OP.
Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer.”
David Waterhouse, Chief Innovation Officer at Oncology-Hematology Care, shared this post on LinkedIn, adding:
“There is no doubt that this class of targeted agents are likely to move into first line NSCLCA treatment. If you are involved in clinical lung cancer research, you want to make sure that such the trial is incorporated into your portfolio.
But, it’s not just going to be just for lung cancer. If anyone knows about tissue agnostic drug development, it is Dr. Subbiah.”
Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer
Authors: Andrew J. Pellatt, Deepak Bhamidipati and Vivek Subbiah
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023